MX2022010666A - Sistema crispr-cas de tipo vi-e y de tipo vi-f y usos del mismo. - Google Patents

Sistema crispr-cas de tipo vi-e y de tipo vi-f y usos del mismo.

Info

Publication number
MX2022010666A
MX2022010666A MX2022010666A MX2022010666A MX2022010666A MX 2022010666 A MX2022010666 A MX 2022010666A MX 2022010666 A MX2022010666 A MX 2022010666A MX 2022010666 A MX2022010666 A MX 2022010666A MX 2022010666 A MX2022010666 A MX 2022010666A
Authority
MX
Mexico
Prior art keywords
type
targeting
novel
crispr
rna
Prior art date
Application number
MX2022010666A
Other languages
English (en)
Inventor
Yingsi Zhou
Hui Yang
Chunlong Xu
Qingquan Xiao
Original Assignee
Huigene Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huigene Therapeutics Co Ltd filed Critical Huigene Therapeutics Co Ltd
Publication of MX2022010666A publication Critical patent/MX2022010666A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/095—Fusion polypeptide containing a localisation/targetting motif containing a nuclear export signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Abstract

Se proporcionan composiciones de CRISPR/Cas novedosas y usos de las mismas para el direccionamiento a ácidos nucleicos. En particular, se proporcionan sistemas de direccionamiento al ARN de origen no natural o modificados por ingeniería genética que comprenden una proteína efectora novedosa Cas13e o Cas13f de direccionamiento al ARN, y al menos un componente de ácido nucleico de direccionamiento, tal como un ARN guía (ARNg) o ARNcr. Las proteínas efectoras Cas novedosas se encuentran entre las más pequeñas de las proteínas efectoras Cas conocidas, con un tamaño de aproximadamente 800 aminoácidos, y, por lo tanto, son excepcionalmente adecuadas para su suministro usando vectores de pequeña capacidad, tales como un vector de AAV.
MX2022010666A 2020-02-28 2020-02-28 Sistema crispr-cas de tipo vi-e y de tipo vi-f y usos del mismo. MX2022010666A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/077211 WO2021168799A1 (en) 2020-02-28 2020-02-28 Type vi-e and type vi-f crispr-cas system and uses thereof

Publications (1)

Publication Number Publication Date
MX2022010666A true MX2022010666A (es) 2023-01-30

Family

ID=74844194

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010666A MX2022010666A (es) 2020-02-28 2020-02-28 Sistema crispr-cas de tipo vi-e y de tipo vi-f y usos del mismo.

Country Status (11)

Country Link
US (2) US11225659B2 (es)
EP (1) EP4110933A4 (es)
JP (2) JP7412586B2 (es)
KR (2) KR102647294B1 (es)
CN (4) CN115315519A (es)
AU (1) AU2020431316A1 (es)
BR (1) BR112022017070A2 (es)
CA (1) CA3169710A1 (es)
IL (1) IL295935A (es)
MX (1) MX2022010666A (es)
WO (1) WO2021168799A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022068912A1 (en) * 2020-09-30 2022-04-07 Huigene Therapeutics Co., Ltd. Engineered crispr/cas13 system and uses thereof
WO2022188039A1 (en) * 2021-03-09 2022-09-15 Huigene Therapeutics Co., Ltd. Engineered crispr/cas13 system and uses thereof
CN115427561A (zh) * 2021-03-09 2022-12-02 辉大(上海)生物科技有限公司 工程化CRISPR/Cas13系统及其用途
CN115386560A (zh) * 2021-05-25 2022-11-25 中国科学院脑科学与智能技术卓越创新中心 在细胞和成体水平检测蛋白质旁切效应的系统
WO2022266849A1 (zh) * 2021-06-22 2022-12-29 中国科学院脑科学与智能技术卓越创新中心 新型CRISPR-Cas13蛋白的筛选及其应用
WO2023274226A1 (en) * 2021-06-29 2023-01-05 Huigene Therapeutics Co., Ltd. Crispr/cas system and uses thereof
CN113832180A (zh) * 2021-08-03 2021-12-24 华中农业大学 CRISPR/Cas13b介导的棉花RNA转录调控方法
WO2023025103A1 (en) * 2021-08-22 2023-03-02 Huigene Therapeutics Co., Ltd. Crispr-cas13 system for treating sod1-associated diseases
WO2023029532A1 (en) * 2021-08-30 2023-03-09 Huigene Therapeutics Co., Ltd. Engineered cas6 protein and uses thereof
WO2023051734A1 (en) * 2021-09-29 2023-04-06 Huidagene Therapeutics Co., Ltd. Engineered crispr-cas13f system and uses thereof
CA3234811A1 (en) 2021-10-20 2023-04-27 Steven Goldman Rejuvenation treatment of age-related white matter loss
CN114015674A (zh) * 2021-11-02 2022-02-08 辉二(上海)生物科技有限公司 新型CRISPR-Cas12i系统
CN116790555A (zh) * 2022-03-14 2023-09-22 上海鲸奇生物科技有限公司 Rna靶向基因编辑工具的开发
WO2023184107A1 (en) * 2022-03-28 2023-10-05 Huigene Therapeutics Co., Ltd. Crispr-cas13 system for treating mecp2-associated diseases
WO2023184108A1 (en) * 2022-03-28 2023-10-05 Huigene Therapeutics Co., Ltd. Crispr-cas13 system for treating ube3a-associated diseases
CN117545839A (zh) * 2022-03-28 2024-02-09 辉大基因治疗(新加坡)私人有限公司 工程化CRISPR-Cas13f系统及其用途
WO2023201203A2 (en) * 2022-04-11 2023-10-19 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof
CN115820603A (zh) * 2022-11-15 2023-03-21 吉林大学 一种基于dCasRx-NSUN6单基因特异性M5C修饰编辑方法
CN116286904B (zh) * 2023-05-10 2023-08-01 内蒙古大学 牛源化CRISPR/boCas13a基因编辑系统、方法及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2658401T3 (es) * 2012-12-12 2018-03-09 The Broad Institute, Inc. Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas
CN105695485B (zh) * 2014-11-27 2020-02-21 中国科学院上海生命科学研究院 一种用于丝状真菌Crispr-Cas系统的Cas9编码基因及其应用
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US20170211142A1 (en) * 2015-10-22 2017-07-27 The Broad Institute, Inc. Novel crispr enzymes and systems
EP3445848A1 (en) * 2016-04-19 2019-02-27 The Broad Institute, Inc. Novel crispr enzymes and systems
JP7267013B2 (ja) * 2016-06-17 2023-05-01 ザ・ブロード・インスティテュート・インコーポレイテッド Ｖｉ型ｃｒｉｓｐｒオルソログ及び系
EP4119663A1 (en) 2016-12-09 2023-01-18 The Broad Institute, Inc. Crispr effector system based diagnostics
KR102185464B1 (ko) 2017-03-15 2020-12-03 매사추세츠 인스티튜트 오브 테크놀로지 신규 cas13b 오르소로그 crispr 효소 및 시스템
US11840711B2 (en) * 2017-04-12 2023-12-12 The Broad Institute, Inc. Type VI CRISPR orthologs and systems
US10392616B2 (en) * 2017-06-30 2019-08-27 Arbor Biotechnologies, Inc. CRISPR RNA targeting enzymes and systems and uses thereof
US10476825B2 (en) * 2017-08-22 2019-11-12 Salk Institue for Biological Studies RNA targeting methods and compositions
WO2019108619A1 (en) * 2017-11-28 2019-06-06 Two Blades Foundation Methods and compositions for enhancing the disease resistance of plants
WO2019204828A1 (en) * 2018-04-20 2019-10-24 The Regents Of The University Of California Fusion proteins and fusion ribonucleic acids for tracking and manipulating cellular rna
CN112020560B (zh) * 2018-04-25 2024-02-23 中国农业大学 一种RNA编辑的CRISPR/Cas效应蛋白及系统
CN108546718B (zh) * 2018-05-16 2021-07-09 康春生 crRNA介导的CRISPR/Cas13a基因编辑系统在肿瘤细胞中的应用
CN110527697B (zh) * 2018-05-23 2023-07-07 中国科学院分子植物科学卓越创新中心 基于CRISPR-Cas13a的RNA定点编辑技术
AU2019314433A1 (en) * 2018-07-31 2021-03-25 Massachusetts Institute Of Technology Novel CRISPR enzymes and systems
EP3830301A1 (en) * 2018-08-01 2021-06-09 Mammoth Biosciences, Inc. Programmable nuclease compositions and methods of use thereof
CN115175996A (zh) * 2019-09-20 2022-10-11 博德研究所 新颖vi型crispr酶和系统

Also Published As

Publication number Publication date
US20220119808A1 (en) 2022-04-21
IL295935A (en) 2022-10-01
CN116121251A (zh) 2023-05-16
CN116590257B (zh) 2024-04-30
JP2023516974A (ja) 2023-04-21
CN116590257A (zh) 2023-08-15
CN115315519A (zh) 2022-11-08
KR20240035924A (ko) 2024-03-18
AU2020431316A2 (en) 2022-12-22
US11225659B2 (en) 2022-01-18
WO2021168799A1 (en) 2021-09-02
CN112410377B (zh) 2022-09-13
JP2024038096A (ja) 2024-03-19
AU2020431316A1 (en) 2022-10-20
CN112410377A (zh) 2021-02-26
KR20230029585A (ko) 2023-03-03
US20210269795A1 (en) 2021-09-02
KR102647294B1 (ko) 2024-03-13
EP4110933A4 (en) 2024-02-21
BR112022017070A2 (pt) 2022-11-16
EP4110933A1 (en) 2023-01-04
CA3169710A1 (en) 2021-09-02
JP7412586B2 (ja) 2024-01-12

Similar Documents

Publication Publication Date Title
MX2022010666A (es) Sistema crispr-cas de tipo vi-e y de tipo vi-f y usos del mismo.
WO2020028555A3 (en) Novel crispr enzymes and systems
EP4257696A3 (en) Novel crispr dna targeting enzymes and systems
CL2021002741A1 (es) Una proteína crispr de prevotella y francisella 1 (cpf1) aislada de lachnospiraceae bacterium nd2006; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004)
WO2004108938A3 (en) Peptide ligands of dendritic cells for nucleic acid vector targeting
EP4253551A3 (en) Novel crispr dna and rna targeting enzymes and systems
Swaisgood et al. The caseins
DK374586D0 (da) Glyphosat-resistente planter og fremgangsmaade til fremstilling deraf samt kimaeriske gener og klonings- eller udtrykkelsesvektorer til anvendelse derved
IL87332A (en) Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology, process, expression vector and recombinant host therefor and pharmaceutical compositions containing them
WO2002086144A3 (en) Compositions and methods for recombinational cloning of nucleic acid molecules
WO2022261150A3 (en) Particle delivery systems
EP2210948A3 (en) Use of multiple recombination sites with unique specificity in recombinational cloning
EP1349917A4 (en) METHOD AND COMPOSITIONS FOR SYNTHESISING NUCLEIC ACID MOLECULES USING MULTIPLE DETECTING POINTS
MX2022002872A (es) Nuevas sistemas y enzimas de crispr dirigidos a adn.
WO2023102329A3 (en) Effector proteins and uses thereof
MX2022013187A (es) Nucleasas guiadas por acido ribonucleico (arn) y sus fragmentos activos y variantes y metodos de uso.
EP4257155A3 (en) Compositions and methods for treating wilson's disease
WO2022115604A3 (en) Long-acting and long-circulating delivery vehicles
PL351652A1 (en) Novel organic anion transport proteins
Tsuprun et al. Electron microscopy of glutamine synthetase from pea leaf chloroplasts
WO2000052164A3 (en) Potassium channel molecules and uses therefor
WO2022119871A3 (en) Novel compositions with tissue-specific targeting motifs and compositions containing same
AU2022360286A1 (en) Synthetic genome editing system
MX2021009161A (es) Acidos nucleicos recombinantes que contienen secuencias promotoras de alfaherpesvirus.
AU2001249649A1 (en) 16836, a novel human phospholipase c family member and uses thereof